A Study in Moderate to Severe Rheumatoid Arthritis
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether baricitinib is superior to placebo in the
treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who
have had an inadequate response to methotrexate (MTX) treatment.